88 results on '"B-Cell Maturation Antigen immunology"'
Search Results
2. Beyond BCMA: newer immune targets in myeloma.
- Author
-
Tan MSY, Chen Y, and Smith EL
- Subjects
- Humans, Immunotherapy methods, Molecular Targeted Therapy, T-Lymphocytes immunology, T-Lymphocytes metabolism, Signaling Lymphocytic Activation Molecule Family antagonists & inhibitors, Signaling Lymphocytic Activation Molecule Family immunology, Signaling Lymphocytic Activation Molecule Family metabolism, Multiple Myeloma therapy, Multiple Myeloma immunology, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology
- Abstract
Abstract: The identification and targeting of B-cell maturation antigen (BCMA) through immunotherapeutic strategies such as antibody-drug conjugates, chimeric antigen receptor T cells, and T-cell engagers have revolutionized the care of patients with multiple myeloma (MM). These treatment modalities have improved the survival outcomes of patients with relapsed and/or refractory MM compared with previously established strategies and are moving into earlier lines of therapy. Despite their efficacy, the majority of patients eventually relapse, necessitating additional therapeutic targets for salvage. G-protein-coupled receptor class 5 member D, Fc receptor-homolog 5, and SLAMF7 are some examples of novel targets in development. This expanding armamentarium of immunotherapeutic agents will be crucial to address the unmet need for relapses after BCMA-targeting therapies, particularly antigen-negative relapses. The utilization of sequential T-cell redirective therapies including agents targeting different tumor-associated antigens and combination therapies appears feasible, paving the way for effective chemotherapy-free regimes. Deliberate consideration of treatment timing, preserving T-cell health, overcoming antigenic loss, and comprehension of the complex tumor microenvironment would be key to maximizing therapeutic benefits and minimizing adverse effects. This review summarizes novel targets in development for myeloma beyond BCMA, presenting pivotal safety and efficacy data derived from clinical trials when available and the considerations vital for navigating this expanding landscape of immunotherapeutic options., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.
- Author
-
Shi X, Wu Y, Yao X, Du B, and Du X
- Subjects
- Humans, Male, Neoplasm Recurrence, Local therapy, Middle Aged, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen genetics, Multiple Myeloma therapy, Multiple Myeloma immunology, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods
- Abstract
Background: The development of CAR-T-cell immunotherapy has notably elevated the efficacy of treating multiple myeloma. Currently, a variety of targets, including BCMA, CS1, CD38, FcRH5, and GPRC5D, are being investigated. Despite these significant advancements, challenges such as antigen escape, limited persistence of CAR-T cells, and the intricate nature of the tumor microenvironment persist, leading to relapses following treatment., Case Presentation: We report the case of a patient with recurrent and refractory multiple myeloma (RRMM) who developed a substantial extramedullary plasmacytoma in the muscles of the lower limb following multiple rounds of radiotherapy and chemotherapy. The patient underwent CAR-T-cell immunotherapy targeting BCMA and CS1; however, the tumor progressed despite treatment. Surgical resection of the extramedullary plasmacytoma was subsequently performed. Upon comparison of the tumor tissue with the adjacent tissue, increased expression of MYBL2 was noted in the tumor tissue, potentially contributing to the lack of improvement in extramedullary relapse after dual-targeted CAR-T cell therapy., Conclusions: In patients with recurrent and refractory multiple myeloma who underwent multiple cycles of chemotherapy and radiotherapy, dual-targeted CAR-T cell therapy aimed at BCMA and CS1 failed to effectively manage extramedullary relapse. Elevated expression of MYBL2 in multiple myeloma correlates with a poorer prognosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Shi, Wu, Yao, Du and Du.)
- Published
- 2024
- Full Text
- View/download PDF
4. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.
- Author
-
Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, Bylsma S, Hansen E, Wolf J, Wong S, Shah N, Roybal KT, Martin T, Ye CJ, and Fong L
- Subjects
- Humans, Recurrence, Male, Female, T-Cell Exhaustion, Multiple Myeloma therapy, Multiple Myeloma immunology, B-Cell Maturation Antigen metabolism, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen metabolism, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism
- Abstract
Abstract: Multiple myeloma is characterized by frequent clinical relapses after conventional therapy. Recently, chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (BCMA) has been established as a treatment option for patients with relapsed or refractory disease. However, although >70% of patients initially respond to this treatment, clinical relapse and disease progression occur in most cases. Recent studies showed persistent expression of BCMA at the time of relapse, indicating that immune-intrinsic mechanisms may contribute to this resistance. Although there were no preexisting T-cell features associated with clinical outcomes, we found that patients with a durable response to CAR T-cell treatment had greater persistence of their CAR T cells than patients with transient clinical responses. They also possessed a significantly higher proportion of CD8+ T-effector memory cells. In contrast, patients with short-lived responses to treatment have increased frequencies of cytotoxic CD4+ CAR T cells. These cells expand in vivo early after infusion but express exhaustion markers (hepatitis A virus cellular receptor 2 [HAVCR2] and T-cell immunoglobulin and mucin domain-containing-3 [TIGIT]) and remain polyclonal. Finally, we demonstrate that nonclassical monocytes are enriched in the myeloma niche and may induce CAR T-cell dysfunction through mechanisms that include transforming growth factor β. These findings shed new light on the role of cytotoxic CD4+ T cells in disease progression after CAR T-cell therapy., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma.
- Author
-
Moles MW, Erdlei H, Menzel L, Massaro M, Fiori A, Bunse M, Schrimpf M, Gerlach K, Gudipati V, Reiser J, Mathavan K, Goodrich JP, Huppa JB, Krönke J, Valamehr B, Höpken UE, and Rehm A
- Subjects
- Humans, Cell Line, Tumor, Cytotoxicity, Immunologic, Multiple Myeloma immunology, Multiple Myeloma therapy, Receptors, CXCR4 metabolism, Receptors, CXCR4 genetics, B-Cell Maturation Antigen immunology, B-Cell Maturation Antigen metabolism, B-Cell Maturation Antigen genetics, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen genetics, Receptors, Chimeric Antigen metabolism, Immunotherapy, Adoptive methods, Chemokine CXCL12 metabolism
- Abstract
Multiple myeloma (MM) is a plasma cell disease with a preferential bone marrow (BM) tropism. Enforced expression of tissue-specific chemokine receptors has been shown to successfully guide adoptively-transferred CAR NK cells towards the malignant milieu in solid cancers, but also to BM-resident AML and MM. For redirection towards BM-associated chemokine CXCL12, we armored BCMA CAR-NK-92 as well as primary NK cells with ectopic expression of either wildtype CXCR4 or a gain-of-function mutant CXCR4
R334X . Our data showed that BCMA CAR-NK-92 and -primary NK cells equipped with CXCR4 gained an improved ability to migrate towards CXCL12 in vitro . Beyond its classical role coordinating chemotaxis, CXCR4 has been shown to participate in T cell co-stimulation, which prompted us to examine the functionality of CXCR4-cotransduced BCMA-CAR NK cells. Ectopic CXCR4 expression enhanced the cytotoxic capacity of BCMA CAR-NK cells, as evidenced by the ability to eliminate BCMA-expressing target cell lines and primary MM cells in vitro and through accelerated cytolytic granule release. We show that CXCR4 co-modification prolonged BCMA CAR surface deposition, augmented ZAP-70 recruitment following CAR-engagement, and accelerated distal signal transduction kinetics. BCMA CAR sensitivity towards antigen was enhanced by virtue of an enhanced ZAP-70 recruitment to the immunological synapse, revealing an increased propensity of CARs to become triggered upon CXCR4 overexpression. Unexpectedly, co-stimulation via CXCR4 occurred in the absence of CXCL12 ligand-stimulation. Collectively, our findings imply that co-modification of CAR-NK cells with tissue-relevant chemokine receptors affect adoptive NK cell therapy beyond improved trafficking and retention within tumor sites., Competing Interests: AR and UH filed a patent application for the BCMA CAR used in this manuscript PCT/WO2017211900A1. AR and UH receive research funds from Fate Therapeutics San Diego, CA. JR, KM, JG, and BV are employees of Fate Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Moles, Erdlei, Menzel, Massaro, Fiori, Bunse, Schrimpf, Gerlach, Gudipati, Reiser, Mathavan, Goodrich, Huppa, Krönke, Valamehr, Höpken and Rehm.)- Published
- 2024
- Full Text
- View/download PDF
6. Toll-like receptor signaling in multiple myeloma cells promotes the expression of pro-survival genes B-cell lymphoma 2 and MYC and modulates the expression of B-cell maturation antigen.
- Author
-
Tryggestad SS, Roseth IA, Aass KR, Ørning NEH, Mjelle R, Hella H, and Standal T
- Subjects
- Humans, Cell Line, Tumor, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Bortezomib pharmacology, Bortezomib therapeutic use, Male, Multiple Myeloma genetics, Multiple Myeloma immunology, Multiple Myeloma metabolism, Signal Transduction, B-Cell Maturation Antigen genetics, B-Cell Maturation Antigen metabolism, B-Cell Maturation Antigen immunology, Toll-Like Receptors metabolism, Proto-Oncogene Proteins c-myc genetics, Proto-Oncogene Proteins c-myc metabolism, Gene Expression Regulation, Neoplastic
- Abstract
Infections are common in plasma cell cancer multiple myeloma (MM) due to disease-related immune deficiencies and cancer treatment. Myeloma cells express Toll-like receptors (TLRs), and TLR activation has been shown to induce proliferative and pro-survival signals in cancer cells. MM is a complex and heterogeneous disease, and expression levels of TLRs as well as downstream signaling components are likely to differ between patients. Here, we show that in a large cohort of patients, TLR1, TLR4, TLR6, TLR9, and TLR10 are the most highly expressed in primary CD138
+ cells. Using an MM cell line expressing TLR4 and TLR9 as a model, we demonstrate that TLR4 and TLR9 activation promoted the expression of well-established pro-survival and oncogenes in MM such as MYC , IRF4 , NFKB , and BCL2 . TLR4 and TLR9 activation inhibited the efficacy of proteasome inhibitors bortezomib and carfilzomib, drugs used in the treatment of MM. Inhibiting the autophagosome-lysosome protein degradation pathway by hydroxychloroquine (HCQ) diminished the protective effect of TLR activation on proteasome inhibitor-induced cytotoxicity. We also found that TLR signaling downregulated the expression of TNFRSF17 , the gene encoding for B-cell maturation antigen (BCMA). MYC , BCL2 , and BCL2L1 were upregulated in approximately 50% of primary cells, while the response to TLR signaling in terms of TNFRSF17 expression was dichotomous, as an equal fraction of patients showed upregulation and downregulation of the gene. While proteasome inhibitors are part of first-line MM treatment, several of the new anti-MM immune therapeutic drugs target BCMA. Thus, TLR activation may render MM cells less responsive to commonly used anti-myeloma drugs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Tryggestad, Roseth, Aass, Ørning, Mjelle, Hella and Standal.)- Published
- 2024
- Full Text
- View/download PDF
7. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
- Author
-
Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Korde N, Shah UA, Tan CR, Hultcrantz M, Giralt SA, Usmani SZ, Shahid Z, Mailankody S, and Lesokhin AM
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Adult, Infections etiology, Infections epidemiology, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific adverse effects, Aged, 80 and over, Incidence, Immunoconjugates therapeutic use, Immunoconjugates adverse effects, Multiple Myeloma therapy, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive adverse effects
- Abstract
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC. The incidence of severe infections was higher with BsAb (40%) than CAR-T (26%) or ADC (8%), including grade 5 infections (7% vs 0% vs 0%, respectively). Comparing T-cell redirecting therapies, the incidence rate of severe infections was significantly lower with CAR-T compared to BsAb at 1-year (incidence-rate-ratio [IRR] = 0.43, 95%CI 0.25-0.76, P = 0.004). During periods of treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates (IRR:2.27, 1.31-3.98, P = 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb. In conclusion, we observed an overall higher and more persistent risk of severe infections with BsAb. Our results also suggest a higher infection risk during periods of hypogammaglobulinemia with BsAb, and with neutropenia in CAR-T recipients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
- Author
-
Lu Q, Li H, Wu Z, Zhu Z, Zhang Z, Yang D, and Tong A
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Single-Domain Antibodies immunology, Single-Domain Antibodies pharmacology, T-Lymphocytes immunology, CRISPR-Cas Systems, Female, Multiple Myeloma therapy, Multiple Myeloma immunology, CD47 Antigen immunology, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen immunology
- Abstract
Background: BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the current preparation process for autologous CAR-T cells is complicated and costly. Moreover, the upregulation of CD47 expression has been observed in multiple myeloma, and anti-CD47 antibodies have shown remarkable results in clinical trials. Therefore, we focus on the development of BCMA/CD47-directed universal CAR-T (UCAR-T) cells to improve these limitations., Methods: In this study, we employed phage display technology to screen nanobodies against BCMA and CD47 protein, and determined the characterization of nanobodies. Furthermore, we simultaneously disrupted the endogenous TRAC and B2M genes of T cells using CRISPR/Cas9 system to generate TCR and HLA double knock-out T cells, and developed BCMA/CD47-directed UCAR-T cells and detected the antitumor activity in vitro and in vivo., Results: We obtained fourteen and one specific nanobodies against BCMA and CD47 protein from the immunized VHH library, respectively. BCMA/CD47-directed UCAR-T cells exhibited superior CAR expression (89.13-98.03%), and effectively killing primary human MM cells and MM cell lines. BCMA/CD47-directed UCAR-T cells demonstrated excellent antitumor activity against MM and prolonged the survival of tumor-engrafted NCG mice in vivo., Conclusions: This work demonstrated that BCMA/CD47-directed UCAR-T cells exhibited potent antitumor activity against MM in vitro and in vivo, which provides a potential strategy for the development of a novel "off-the-shelf" cellular immunotherapies for the treatment of multiple myeloma., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
- Author
-
Hanssens H, Meeus F, Gesquiere EL, Puttemans J, De Vlaeminck Y, De Veirman K, Breckpot K, and Devoogdt N
- Subjects
- Humans, Animals, Mice, T-Lymphocytes immunology, T-Lymphocytes metabolism, Cell Line, Tumor, Antibodies, Anti-Idiotypic immunology, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen metabolism, B-Cell Maturation Antigen immunology, B-Cell Maturation Antigen metabolism, Immunoglobulin Heavy Chains immunology, Immunoglobulin Heavy Chains chemistry, Single-Chain Antibodies immunology, Single-Domain Antibodies immunology, Single-Domain Antibodies chemistry, Lymphocyte Activation immunology, Multiple Myeloma immunology, Multiple Myeloma therapy, Immunotherapy, Adoptive methods
- Abstract
CAR-T cell therapy is at the forefront of next-generation multiple myeloma (MM) management, with two B-cell maturation antigen (BCMA)-targeted products recently approved. However, these products are incapable of breaking the infamous pattern of patient relapse. Two contributing factors are the use of BCMA as a target molecule and the artificial scFv format that is responsible for antigen recognition. Tackling both points of improvement in the present study, we used previously characterized VHHs that specifically target the idiotype of murine 5T33 MM cells. This idiotype represents one of the most promising yet challenging MM target antigens, as it is highly cancer- but also patient-specific. These VHHs were incorporated into VHH-based CAR modules, the format of which has advantages compared to scFv-based CARs. This allowed a side-by-side comparison of the influence of the targeting domain on T cell activation. Surprisingly, VHHs previously selected as lead compounds for targeted MM radiotherapy are not the best (CAR-) T cell activators. Moreover, the majority of the evaluated VHHs are incapable of inducing any T cell activation. As such, we highlight the importance of specific VHH selection, depending on its intended use, and thereby raise an important shortcoming of current common CAR development approaches.
- Published
- 2024
- Full Text
- View/download PDF
10. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity.
- Author
-
Bodansky A, Yu DJ, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green DJ, Gauthier J, Turtle CJ, Zorn K, O'Donovan B, Mandel-Brehm C, Asaki J, Kortbawi H, Kung AF, Rackaityte E, Wang CY, Saxena A, de Dios K, Masi G, Nowak RJ, O'Connor KC, Li H, Diaz VE, Saloner R, Casaletto KB, Gontrum EQ, Chan B, Kramer JH, Wilson MR, Utz PJ, Hill JA, Jackson SW, Anderson MS, and DeRisi JL
- Subjects
- Humans, Female, Autoimmune Diseases immunology, Autoimmune Diseases therapy, Male, Immunotherapy, Adoptive methods, B-Cell Maturation Antigen immunology, B-Cell Maturation Antigen metabolism, Adult, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen metabolism, Antigens, CD19 immunology, Middle Aged, Proteome, Autoantibodies immunology, Autoimmunity
- Abstract
Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leveraged advances in programmable-phage immunoprecipitation methodology to explore the modulation, or lack thereof, of autoantibody profiles, proteome-wide, in both health and disease. Using a custom set of over 730,000 human-derived peptides, we demonstrated that each individual, regardless of disease state, possesses a distinct and complex constellation of autoreactive antibodies. For each individual, the set of resulting autoreactivites constituted a unique immunological fingerprint, or "autoreactome," that was remarkably stable over years. Using the autoreactome as a primary output, we evaluated the relative effectiveness of various immunomodulatory therapies in altering autoantibody repertoires. We found that therapies targeting B cell maturation antigen (BCMA) profoundly altered an individual's autoreactome, while anti-CD19 and anti-CD20 therapies had minimal effects. These data both confirm that the autoreactome comprises autoantibodies secreted by plasma cells and strongly suggest that BCMA or other plasma cell-targeting therapies may be highly effective in treating currently refractory autoantibody-mediated diseases.
- Published
- 2024
- Full Text
- View/download PDF
11. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
- Author
-
Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, and Chung A
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Retreatment, Adult, Treatment Outcome, Recurrence, Receptors, Chimeric Antigen therapeutic use, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Multiple Myeloma therapy, Multiple Myeloma mortality, Multiple Myeloma immunology, Salvage Therapy methods, Immunotherapy, Adoptive methods
- Abstract
Abstract: For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T), optimal salvage treatment strategies remain unclear. BCMA-directed CAR-T and bispecific antibodies (BsAbs) are now commercially available, and the outcomes for retreatment with BCMA-directed approaches are not well studied. We performed a retrospective analysis of 68 patients with relapsed disease after BCMA-directed CAR-T to evaluate outcomes and responses to salvage therapies. With a median follow-up of 13.5 months, median overall survival from time of relapse until death was 18 months (95% confidence interval [CI], 13.2 to not reached [NR]). Fifty-eight patients received subsequent myeloma-directed therapies, with a total of 265 lines of therapy (LOTs). The overall response rate for firstline salvage therapy was 41% (95% CI, 28-55). Among all LOTs, high response rates were observed among those receiving another BCMA-directed CAR-T (89%), BCMA-directed BsAbs (60%), CD38-directed combinations (80% when combined with BsAb; 50% when combined with immunomodulatory drugs and/or proteasome inhibitors), and alkylator-combinations (50% overall; 69% with high-dose alkylators). Thirty-four patients received at least 1 line of salvage BCMA-directed therapy; median progression-free survival was 8.3 months (95% CI, 7.9 to NR), 3.6 months (95% CI, 1.4 to NR), and 1 month (95% CI, 0.9 to NR) with median duration of response (DOR) of 8 months, 4.4 months, and 2.8 months for subsequent BCMA-directed CAR-T, BsAb, and belantamab mafadotin, respectively. Retreatment with BCMA-directed CAR-T and BsAbs can be effective salvage options after BCMA-directed CAR-T relapse; however, DORs appear limited, and further studies with new combinations and alternative targets are warranted., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
- Author
-
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, and Alsina M
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Biological Products therapeutic use, Biological Products administration & dosage, Adult, B-Cell Maturation Antigen immunology, Antigens, CD19 immunology, Antigens, CD19 therapeutic use, Recurrence, Treatment Outcome, Aged, 80 and over, Drug Resistance, Neoplasm, United States epidemiology, Recombinant Fusion Proteins administration & dosage, Recombinant Fusion Proteins therapeutic use, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen therapeutic use, Risk Factors, Multiple Myeloma therapy, Multiple Myeloma immunology, Multiple Myeloma mortality, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive adverse effects, Disease Progression
- Abstract
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors associated with early progression (progression or death due to myeloma ≤3 months after CAR T-cell infusion) in patients treated with standard of care ide-cel at 11 US academic centers. Among 211 patients that received ide-cel, 43 patients had a progressive event ≤3 months of infusion. Patients with a history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, use of bridging therapy, Hispanic ethnicity, plasma cell leukemia and t(4;14) were more likely to progress ≤3 months of infusion (P<0.05). Of these risk factors for early progression identified in univariate analyses, history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, plasma cell leukemia, and t(4;14) were associated with worse progression-free survival (PFS) in multivariable analysis. Presence of three or more of these factors had a significant negative impact on PFS (P<0.001; median PFS for ≥3 factors, 3.2 months vs. 0 factors, 14.1 months). This study helps identify patients at high risk of early progression after CAR T-cell therapy who may benefit from specific interventions pre and post CAR T-cell therpy to improve outcomes.
- Published
- 2024
- Full Text
- View/download PDF
13. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
- Author
-
Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, He AL, Mi JQ, and Chen SJ
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Follow-Up Studies, Receptors, Chimeric Antigen therapeutic use, Receptors, Chimeric Antigen immunology, Remission Induction, Survival Rate, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive adverse effects, Multiple Myeloma therapy, Multiple Myeloma mortality
- Abstract
Background: The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up., Methods: Participants received an average dose of 0.5 × 10
6 cells/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated., Results: Seventy-four participants enrolled and had a median follow-up of 65.4 months. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 21.0% and 49.1%, with progressive flattening of the survival curves over time. Patients with complete response (CR) had longer PFS and OS, with 5-year rates of 28.4% and 65.7%, respectively. Twelve patients (16.2%) remained relapse-free irrespective of baseline high-risk cytogenetic abnormality and all had normal humoral immunity reconstituted. An ongoing CR closely correlated with several prognostic baseline indices including favorable performance status, immunoglobulin G subtype, and absence of extramedullary disease, as well as a combination cyclophosphamide and fludarabine preconditioning strategy. Sixty-two (83.8%) suffered progressive disease (PD) and/or death; however, 61.1% of PD patients could well respond to subsequent therapies, among which, the proteasome inhibitor-based regimens benefited the most. Concerning the safety, hematologic and hepatic function recovery were not significantly different between non-PD and PD/Death groups. A low rate of second primary malignancy (5.4%) and no severe virus infection were observed. The patients who tested positive for COVID-19 merely presented self-limiting symptoms. In addition, a sustainable CAR T population of one case with persistent remission was delineated, which was enriched with indolently proliferative and lowly cytotoxic CD4/CD8 double-negative functional T lymphocytes., Conclusions: These data, representing the longest follow-up of BCMA-redirected CAR T-cell therapy to date, demonstrate long-term remission and survival with LCAR-B38M for advanced myeloma., Trial Registration: LEGEND-2 was registered under the trial numbers NCT03090659, ChiCTRONH-17012285., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
14. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
- Author
-
Gao SQ, Mu J, Li X, Wang J, Cui R, Li JY, Sui T, and Deng Q
- Subjects
- Humans, Bone Marrow metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism, Male, Middle Aged, Female, Multiple Myeloma therapy, B-Cell Maturation Antigen immunology, Receptors, Chimeric Antigen immunology, Immunotherapy, Adoptive methods
- Abstract
Objective: The effect of bone marrow soluble B cell maturation antigen (sBCMA) expression on the efficacy and side effects of chimeric antigen receptor (CAR) -modified T-cell-targeting B cell maturation antigen (BCMA) in patients with multiple myeloma (MM) . Methods: This study involved 29 patients with relapsed or refractory MM (RRMM) who received humanized anti-BCMA CAR-T cell clinical trials from January 2018 to December 2021. The expression of sBCMA in bone marrow before and after anti-BCMA CAR-T cell treatment was detected by flow cytometry and compared. Results: ①Two months after BCMA CAR-T cell treatment, 20 patients (68.97%) achieved an overall response (OR), whereas nine patients had stable disease (SD) or miner emission (MR). ②The expression of sBCMA in the bone marrow of 20 patients with OR was higher before treatment than after [26 926 (18 215, 32 488) ng/L vs 9 968 (6 634, 11 459) ng/L; P <0.001]; no significant difference was observed in patients with MR and SD [41 187 (33 816, 47 046) ng/L vs. 33 954 (31 569, 36 256) ng/L; P =0.145]; sBCMA expression in patients with OR before CAR-T cell treatment was lower than in patients with MR and SD ( P =0.005). ③No significant linear correlation was found between the peak value of CAR-T cells and sBCMA expression in the bone marrow of all 29 patients with RRMM ( R (2)=0.035, P =0.330). ④No significant difference in sBCMA expression was found between grades 0-1 CRS group (13 patients) and grades 2-4 CRS group [16 patients; 32 045 (18 742, 40 801) ng/L vs 29 102 (24 679, 38 776) ng/L, P =0.879], nor between grade 0 ICANS group (22 patients) and grade 1-3 ICANS group [seven patients; 30 073 (19 375, 40 065) ng/L vs 33 816 (22 933, 43 459) ng/L, P =0.763]. Conclusion: sBCMA expression in the bone marrow is related to the efficacy of BCMA CAR-T cell therapy in patients with RRMM, but is not significantly correlated with the severity of adverse events. It may serve as a predictive biomarker for the efficacy of BCMA CAR-T cell therapy in these patients.
- Published
- 2024
- Full Text
- View/download PDF
15. Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.
- Author
-
Uttervall K, Tätting L, Lemonakis K, Majd M, Crafoord J, Olsson M, Mellqvist UH, Hansson M, and Nahi H
- Subjects
- Humans, Sweden epidemiology, Male, Middle Aged, Female, Aged, Aged, 80 and over, Adult, T-Lymphocytes immunology, Treatment Outcome, Progression-Free Survival, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological adverse effects, Multiple Myeloma drug therapy, Multiple Myeloma immunology, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific adverse effects
- Abstract
Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections., Methods/results: This study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months., Conclusions: Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real-world data highlight the potential of BCMA T-cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks., (© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
16. CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment.
- Author
-
Graham CE and Maus MV
- Subjects
- Humans, B-Cell Maturation Antigen immunology, Bone Marrow immunology, T-Lymphocytes immunology, Tumor Microenvironment, Multiple Myeloma blood, Receptors, Chimeric Antigen, Bone Marrow Neoplasms
- Abstract
In this issue of Blood Cancer Discovery, Dhodapkar and colleagues find that myeloid, dendritic, and endogenous T-cell populations in the bone marrow microenvironment are associated with progression-free survival (PFS) in multiple myeloma patients responding to B-cell maturation antigen-targeted CAR T cells. Immunosuppressive myeloid cells are associated with short PFS, but a diverse T-cell receptor repertoire and more dendritic cells are associated with a longer PFS, suggesting a potential role for epitope spreading. See related article by Dhodapkar et al., p. 490 (6)., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
17. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
- Author
-
Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, Dunmire S, Jones BJ, Lahr WS, Webber BR, Moriarity BS, Caimi P, and Parameswaran R
- Subjects
- Animals, Antigens, CD genetics, Antigens, CD immunology, Antigens, Differentiation, T-Lymphocyte genetics, Antigens, Differentiation, T-Lymphocyte immunology, B-Cell Activating Factor immunology, B-Cell Activation Factor Receptor immunology, B-Cell Maturation Antigen immunology, B-Lymphocytes immunology, B-Lymphocytes pathology, Cell Line, Tumor, Coculture Techniques, Cytotoxicity, Immunologic, Female, Gene Expression Regulation, Neoplastic, Humans, Lectins, C-Type genetics, Lectins, C-Type immunology, Lymphocyte Activation, Lymphoma, Mantle-Cell genetics, Lymphoma, Mantle-Cell immunology, Lymphoma, Mantle-Cell pathology, Lysosomal-Associated Membrane Protein 1 genetics, Lysosomal-Associated Membrane Protein 1 immunology, Male, Mice, Multiple Myeloma genetics, Multiple Myeloma immunology, Multiple Myeloma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Protein Binding, Receptors, Chimeric Antigen genetics, Receptors, Chimeric Antigen immunology, Signal Transduction, T-Lymphocytes immunology, T-Lymphocytes transplantation, Transmembrane Activator and CAML Interactor Protein immunology, Xenograft Model Antitumor Assays, B-Cell Activating Factor genetics, B-Cell Activation Factor Receptor genetics, B-Cell Maturation Antigen genetics, Lymphoma, Mantle-Cell therapy, Multiple Myeloma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Transmembrane Activator and CAML Interactor Protein genetics
- Abstract
B cell-activating factor (BAFF) binds the three receptors BAFF-R, BCMA, and TACI, predominantly expressed on mature B cells. Almost all B cell cancers are reported to express at least one of these receptors. Here we develop a BAFF ligand-based chimeric antigen receptor (CAR) and generate BAFF CAR-T cells using a non-viral gene delivery method. We show that BAFF CAR-T cells bind specifically to each of the three BAFF receptors and are effective at killing multiple B cell cancers, including mantle cell lymphoma (MCL), multiple myeloma (MM), and acute lymphoblastic leukemia (ALL), in vitro and in vivo using different xenograft models. Co-culture of BAFF CAR-T cells with these tumor cells results in induction of activation marker CD69, degranulation marker CD107a, and multiple proinflammatory cytokines. In summary, we report a ligand-based BAFF CAR-T capable of binding three different receptors, minimizing the potential for antigen escape in the treatment of B cell cancers., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
18. First CAR for multiple myeloma.
- Author
-
O'Leary K
- Subjects
- Humans, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology
- Published
- 2021
- Full Text
- View/download PDF
19. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.
- Author
-
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, Kim-Schulze S, Rahman A, Laganà A, Brody JD, Merad M, Jagannath S, and Parekh S
- Subjects
- Humans, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Movement Disorders therapy, Parkinsonian Disorders therapy, Receptors, Chimeric Antigen immunology
- Abstract
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case of a patient with MM who was enrolled in the CARTITUDE-1 trial ( NCT03548207 ) and who developed a progressive movement disorder with features of parkinsonism approximately 3 months after ciltacabtagene autoleucel BCMA-targeted CAR-T cell infusion, associated with CAR-T cell persistence in the blood and cerebrospinal fluid, and basal ganglia lymphocytic infiltration. We show BCMA expression on neurons and astrocytes in the patient's basal ganglia. Public transcriptomic datasets further confirm BCMA RNA expression in the caudate of normal human brains, suggesting that this might be an on-target effect of anti-BCMA therapy. Given reports of three patients with grade 3 or higher parkinsonism on the phase 2 ciltacabtagene autoleucel trial and of grade 3 parkinsonism in the idecabtagene vicleucel package insert, our findings support close neurological monitoring of patients on BCMA-targeted T cell therapies., (© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
20. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
- Author
-
Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, Li J, and Chen L
- Subjects
- Humans, Immunotherapy, Adoptive adverse effects, Multiple Myeloma immunology, Progression-Free Survival, Receptors, Chimeric Antigen genetics, Receptors, Chimeric Antigen immunology, Treatment Outcome, B-Cell Maturation Antigen immunology, Cell- and Tissue-Based Therapy, Immunotherapy, Adoptive methods, Multiple Myeloma therapy, Receptors, Chimeric Antigen therapeutic use
- Abstract
Background: Chimeric antigen receptor (CAR) T-cell therapy shows impressive results in clinical trials. We conducted a meta-analysis based on the most recent data to systematically describe the efficacy and safety of anti-BCMA CAR T therapy for patients with relapsed or refractory multiple myeloma (R/R MM)., Methods: PubMed, Embase, Web of Science, Cochrane library, ClinicalTrials.gov, China Biology Medicine disc (CBM disc) and Wanfang Data were searched on 8 November 2020. Registration number of PROSPERO was CRD42020219127., Results: From 763 articles, we identified 22 appropriate studies with 681 patients. The pooled overall response rate (ORR) was 85.2% (95%CI 0.797-0.910), complete response rate (CRR) was 47.0% (95%CI 0.378-0.583), and minimal residual disease (MRD) negativity rate was 97.8% (95%CI 0.935-1.022). The pooled incidence of grade 3-4 cytokine release syndrome was 6.6% (95%CI 0.036-0.096) and neurotoxicity was 2.2% (95%CI 0.006-0.038). The median progression-free survival (PFS) was 14.0 months and median overall survival (OS) was 24.0 months. Subgroup analysis showed dual epitope-binding CAR T cells achieved the best therapy outcomes and humanized CAR T cells had the best safety profile. Patients who were older, heavily pre-treated or received lower dose of CAR T cells had worse ORR. There was no significant difference in ORR, CRR and PFS between patients with and without high-risk cytogenetic features. The PFS and CRR of non-extramedullary disease (EMD) group was superior to those of EMD group., Conclusion: Anti-BCMA CAR T therapy is effective and safe for patients with R/R MM. It can improve the prognosis of patients with high-risk cytogenetic features while the prognosis of patients with EMD remains poor. Moreover, patients are likely to benefit from an earlier use of CAR T therapy and human-derived CAR T cells have obvious advantages based on the existing data.
- Published
- 2021
- Full Text
- View/download PDF
21. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.
- Author
-
Ma T, Shi J, Xiao Y, Bian T, Wang J, Hui L, Wang M, and Liu H
- Subjects
- Female, Humans, Immunoglobulins immunology, Immunotherapy, Adoptive, Male, Middle Aged, Neoplasm Staging, Prognosis, Receptors, Chimeric Antigen, B-Cell Maturation Antigen immunology, Bone Marrow immunology, Multiple Myeloma classification, Multiple Myeloma immunology, Multiple Myeloma pathology, Multiple Myeloma therapy
- Abstract
The expression level of BCMA in bone marrow of 54 MM patients was detected in this study to explore the relationship between the BCMA expression and the classification, stage, and prognostic factors of MM. The BCMA expression level of the stable group and remission group was lower than that of the newly diagnosed group and relapse group (P=0.001). There was no significant difference in BCMA expression of MM patients in different types and stages (P>0.05), but it was found that for the newly diagnosed MM patients, the BCMA expression level of IgG patients was higher than that of IgA or light-chain patients (rank average 11.20 vs 5.44, P=0.014). There was no significant correlation between the BCMA expression and the age and serum creatinine of MM patients (P>0.05). And there was no significant difference in BCMA expression between patients with different levels of age and serum creatinine (P>0.05). But it was found that the BCMA expression level of the newly diagnosed MM patients was moderately positively correlated with their age (P=0.025, r=0.595). There was no significant correlation between the BCMA expression and serum β2-microglobulin, serum lactate dehydrogenase, free kap/lam ratio, and urine β2-microglobulin (P>0.05). But we found that the BCMA expression of patients with high serum β2-microglobulin was higher than that of patients with low serum β2-microglobulin (rank average 28.89 vs 17.54, P=0.017). And the BCMA expression of patients with abnormal serum free kap/lam ratio was higher than that of patients with normal ratio (rank average 28.49 vs 13.55, P=0.004). The BCMA expression was strongly positively correlated with 24-h urine protein, was moderately positively correlated with serum M protein and the percentage of plasma cells in bone marrow, was moderately negatively correlated with albumin and hemoglobin count, and was weakly positively correlated with serum corrected calcium (P<0.05). And it was found that the BCMA expression of positive serum immunofixation electrophoresis patients was higher than that of negative patients (rank average 29.94 vs 16.75, P=0.017). And we try to clarify the relationship between the bone marrow BCMA expression and the peripheral blood sBCMA expression. However, we have not found a clear correlation between them so far (P>0.05)., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ma, Shi, Xiao, Bian, Wang, Hui, Wang and Liu.)
- Published
- 2021
- Full Text
- View/download PDF
22. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
- Author
-
Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, Yin P, Wang Z, Ai L, Ke S, Xia Y, Deng J, Chen L, Cai L, Sun C, Xia L, Hua G, and Hu Y
- Subjects
- ADP-ribosyl Cyclase 1 antagonists & inhibitors, Adult, Aged, Animals, B-Cell Maturation Antigen antagonists & inhibitors, Cell Line, Tumor, Female, Humans, Immunotherapy, Adoptive adverse effects, Male, Mice, Middle Aged, Molecular Docking Simulation, Multiple Myeloma immunology, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local therapy, Receptors, Chimeric Antigen immunology, ADP-ribosyl Cyclase 1 immunology, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Multiple Myeloma therapy, Receptors, Chimeric Antigen therapeutic use
- Abstract
Background: BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations., Methods: We constructed a humanized bispecific BM38 CAR targeting BCMA and CD38 and tested the antimyeloma activity of BM38 CAR-Ts in vitro and in vivo. Twenty-three patients with RRMM received infusions of BM38 CAR-Ts in a phase I trial., Results: BM38 CAR-Ts showed stronger in vitro cytotoxicity to heterogeneous MM cells than did T cells expressing an individual BCMA or CD38 CAR. BM38 CAR-Ts also exhibited potent antimyeloma activity in xenograft mouse models. In the phase I trial, cytokine release syndrome occurred in 20 patients (87%) and was mostly grade 1-2 (65%). Neurotoxicity was not observed. Hematologic toxicities were common, including neutropenia in 96% of the patients, leukopenia in 87%, anemia in 43% and thrombocytopenia in 61%. At a median follow-up of 9.0 months (range 0.5 to 18.5), 20 patients (87%) attained a clinical response and minimal residual disease-negativity (≤ 10
-4 nucleated cells), with 12 (52%) achieving a stringent complete response. Extramedullary plasmacytoma was eliminated completely in 56% and partially in 33% and of 9 patients. The median progression-free survival was 17.2 months. Two relapsed patients maintained BCMA and CD38 expression on MM cells. Notably, BM38 CAR-Ts cells were detectable in 77.8% of evaluable patients at 9 months and 62.2% at 12 months., Conclusion: Bispecific BM38 CAR-Ts were feasible, safe and significantly effective in patient with RRMM., Trial Registration: Chictr.org.cn ChiCTR1800018143., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
23. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo .
- Author
-
Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, Seestaller-Wehr L, Kaczynski H, Shi H, Dobrzynski E, Obert L, Tsvetkov L, Cooper DC, Jackson H, Bojczuk P, Forveille S, Kepp O, Sauvat A, Kroemer G, Creighton-Gutteridge M, Yang J, Hopson C, Yanamandra N, Shelton C, Mayes P, Opalinska J, Barnette M, Srinivasan R, Smothers J, and Hoos A
- Subjects
- Animals, Antibodies, Monoclonal chemistry, Apoptosis, B-Cell Maturation Antigen immunology, Cell Proliferation, Female, Humans, Lymphoma immunology, Lymphoma metabolism, Lymphoma pathology, Mice, Mice, Inbred C57BL, Multiple Myeloma immunology, Multiple Myeloma metabolism, Multiple Myeloma pathology, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Antibodies, Monoclonal, Humanized pharmacology, B-Cell Maturation Antigen antagonists & inhibitors, CD8-Positive T-Lymphocytes immunology, Immunoconjugates pharmacology, Immunogenic Cell Death, Lymphoma drug therapy, Multiple Myeloma drug therapy
- Abstract
B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody-drug conjugate approved for the treatment of relapsed/refractory multiple myeloma. We report that GSK2857916 induces immunogenic cell death in BCMA-expressing cancer cells and promotes dendritic cell activation in vitro and in vivo GSK2857916 treatment enhances intratumor immune cell infiltration and activation, delays tumor growth, and promotes durable complete regressions in immune-competent mice bearing EL4 lymphoma tumors expressing human BCMA (EL4-hBCMA). Responding mice are immune to rechallenge with EL4 parental and EL4-hBCMA cells, suggesting engagement of an adaptive immune response, immunologic memory, and tumor antigen spreading, which are abrogated upon depletion of endogenous CD8
+ T cells. Combinations with OX40/OX86, an immune agonist antibody, significantly enhance antitumor activity and increase durable complete responses, providing a strong rationale for clinical evaluation of GSK2857916 combinations with immunotherapies targeting adaptive immune responses, including T-cell-directed checkpoint modulators., (©2021 The Authors; Published by the American Association for Cancer Research.)- Published
- 2021
- Full Text
- View/download PDF
24. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
- Author
-
Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, and Deng Q
- Subjects
- Adult, Aged, B-Cell Maturation Antigen immunology, Comorbidity, Disease Management, Drug Resistance, Neoplasm, Female, Humans, Immunotherapy, Adoptive adverse effects, Male, Middle Aged, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Neoplasm Metastasis, Prognosis, Receptors, Chimeric Antigen genetics, Recurrence, Retreatment, Tomography, X-Ray Computed, Treatment Outcome, B-Cell Maturation Antigen antagonists & inhibitors, Immunotherapy, Adoptive methods, Multiple Myeloma immunology, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology
- Abstract
In recent years, many new treatments for relapsed/refractory (R/R) multiple myeloma (MM) have improved patient prognosis, but the prognosis of patients with extramedullary MM is still particularly poor. Therefore, more efficacious therapies and novel strategies are urgently needed for these patients. The aim of this study was to observe and compare the efficacy and safety of humanized anti-B cell maturation antigen (anti-BCMA) chimeric antigen receptor (CAR) T cell therapy in R/R MM patients with and without extramedullary disease. Seven R/R MM patients with extramedullary disease and 13 without extramedullary disease received humanized anti-BCMA CAR T cell therapy. The overall response rate was not different between patients with and without extramedullary disease. There was no difference in the progression-free survival (PFS) or overall survival (OS) rates between the two groups at 180 days, but the PFS and OS rates in patients with extramedullary disease were lower at 360 days than those in patients without extramedullary disease. Although some patients with extramedullary disease experienced further disease progression, their M protein level did not increase. We did not see this change trend of M protein in patients without extramedullary disease. However, this was not observed in patients without extramedullary disease. Among patients who responded to CAR T cell therapy, the grades of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxic syndrome (ICANS) were much higher among patients with extramedullary disease. In summary, R/R MM patients with extramedullary disease could benefit from humanized anti-BCMA CAR T cell therapy in the short term, although the CRS and ICANS grades were much higher in patients with extramedullary disease. Therefore, anti-BCMA CAR T cell therapy allows for a remission time for R/R MM patients with extramedullary disease, which could be maintained by bridging hematopoietic stem cell transplantation, radiotherapy, and other therapies., Clinical Trial Registration: http://www.chictr.org.cn/index.aspx, identifiers ChiCTR1800017051 and ChiCTR2000033925., Competing Interests: Author JY was employed by the company Shanghai Genbase Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest, (Copyright © 2021 Deng, Liu, Yuan, Zhang, Cui, Li, Yuan, Wang, Wang and Deng.)
- Published
- 2021
- Full Text
- View/download PDF
25. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
- Author
-
Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, and Ferron-Brady G
- Subjects
- Aged, Antibodies, Monoclonal, Humanized administration & dosage, B-Cell Maturation Antigen immunology, Dose-Response Relationship, Drug, Female, Humans, Linear Models, Male, Multiple Myeloma pathology, Nonlinear Dynamics, Randomized Controlled Trials as Topic, Tissue Distribution, Antibodies, Monoclonal, Humanized pharmacokinetics, Models, Biological, Multiple Myeloma drug therapy
- Abstract
Belantamab mafodotin (belamaf) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). Nonlinear mixed-effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine-maleimidocaproyl-MMAF (cys-mcMMAF) after 0.03-4.6 mg/kg dosing every 3 weeks in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM; DREAMM-1, n = 73; DREAMM-2, n = 218). Sequential modeling methodology was used. Individual post hoc parameter estimates from the final ADC model were used to develop total mAb and cys-mcMMAF models. Formal covariate selection used a modified stepwise forward inclusion method with backward elimination. A linear, two-compartment PopPK model with a time-varying clearance (CL) described ADC PK. Initial ADC typical value for CL for a DREAMM-2 patient was 0.936 L/day with a half-life of 11.5 days, over time CL was reduced by 28% resulting in a half-life of 14.3 days. Time to 50% maximal CL change was ~ 50 days. Baseline soluble BCMA (sBCMA), immunoglobulin (IgG), albumin, and bodyweight impacted ADC CL. Cys-mcMMAF concentrations were described with a linear two-compartment model linked to ADC; input rate was governed by deconjugation/intracellular proteolytic degradation of ADC represented by an exponentially decreasing MMAF:mAb (drug antibody ratio [DAR]) after each dose. Time to 50% DAR reduction was 10.3 days. Baseline sBCMA and IgG impacted cys-mcMMAF central volume of distribution. In conclusion, ADC, total mAb, and cys-mcMMAF concentration-time profiles in RRMM were well-described by PopPK models, and exposure was most strongly impacted by disease-related characteristics., (© 2021 GlaxoSmithKline. CPT: Pharmacometrics & Systems publihed by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2021
- Full Text
- View/download PDF
26. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
- Author
-
Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, Jiang L, Meng L, Yang Y, Zhou X, Hong Z, Yao Z, Xiao M, Chen L, Mao X, Zhu L, Wang J, Qiu L, Li C, and Zhou J
- Subjects
- Adult, Afibrinogenemia etiology, Aged, Animals, Antibodies, Anti-Idiotypic biosynthesis, Antineoplastic Agents therapeutic use, B-Cell Maturation Antigen immunology, Combined Modality Therapy, Drug Resistance, Neoplasm, Female, Hematologic Diseases etiology, Humans, Immunity, Humoral, Leukemia, Plasma Cell etiology, Leukemia, Plasma Cell therapy, Male, Mice, Middle Aged, Multiple Myeloma drug therapy, Receptors, Chimeric Antigen administration & dosage, Receptors, Chimeric Antigen immunology, Remission Induction, Single-Chain Antibodies immunology, Transgenes, B-Cell Maturation Antigen antagonists & inhibitors, Immunotherapy, Adoptive adverse effects, Multiple Myeloma therapy, Receptors, Chimeric Antigen therapeutic use, Single-Chain Antibodies therapeutic use
- Abstract
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non-human originated antigen-targeting domain may limit clinical efficacy, we developed a fully human BCMA-specific CAR, CT103A, and report its safety and efficacy in a phase 1 trial. Eighteen consecutive patients with RRMM, including 4 with prior murine BCMA CAR exposures, were enrolled. CT103A was administered at 1, 3, and 6 × 106 CAR-positive T cells/kg in the dose-escalation phase, and 1 × 106 CAR-positive T cells/kg in the expansion cohort. The overall response rate was 100%, with 72.2% of the patients achieving complete response or stringent complete response. For the 4 murine BCMA CAR-exposed patients, 3 achieved stringent complete response, and 1 achieved a very good partial response. At 1 year, the progression-free survival rate was 58.3% for all cohorts and 79.1% for the patients without extramedullary myeloma. Hematologic toxicities were the most common adverse events; 70.6% of the patients experienced grade 1 or 2 cytokine release syndromes. No immune effector cell-associated neurotoxicity syndrome was observed. To the cutoff date, CAR transgenes were detectable in 77.8% of the patients. The median CAR transgene persistence was 307.5 days. Only 1 patient was positive for the anti-drug antibody. Altogether, CT103A is safe and highly active in patients with RRMM and can be developed as a promising therapy for RRMM. Patients who relapsed from prior murine BCMA CAR T-cell therapy may still benefit from CT103A. This trial was registered at http://www.chictr.org.cn as #ChiCTR1800018137., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
27. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
- Author
-
Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, Xu X, Wang C, Zhao S, Lv L, Long J, Lin D, Zhao A, Fang B, Jiang J, Tang S, and Gao J
- Subjects
- Aged, Animals, B-Cell Maturation Antigen antagonists & inhibitors, Cell Line, Tumor, Disease Models, Animal, Drug Resistance, Neoplasm, Female, Gene Order, Genetic Vectors genetics, Humans, Immunologic Memory, Immunophenotyping, Male, Mice, Middle Aged, Multiple Myeloma diagnosis, Multiple Myeloma genetics, Recurrence, Retreatment, Treatment Outcome, Xenograft Model Antitumor Assays, B-Cell Maturation Antigen immunology, Chemokine CCL19 biosynthesis, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive methods, Interleukin-7 biosynthesis, Multiple Myeloma immunology, Multiple Myeloma therapy, T-Lymphocytes immunology, T-Lymphocytes metabolism
- Abstract
Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment, particularly in malignant hematological tumors. Currently, the BCMA-targeted second-generation CAR-T cells have showed impressive efficacy in the treatment of refractory/relapsed multiple myeloma (R/R MM), but up to 50% relapse remains to be addressed urgently. Here we constructed the BCMA-targeted fourth-generation CAR-T cells expressing IL-7 and CCL19 (i.e., BCMA-7 × 19 CAR-T cells), and demonstrated that BCMA-7 × 19 CAR-T cells exhibited superior expansion, differentiation, migration and cytotoxicity. Furthermore, we have been carrying out the first-in-human clinical trial for therapy of R/R MM by use of BCMA-7 × 19 CAR-T cells (ClinicalTrials.gov Identifier: NCT03778346), which preliminarily showed promising safety and efficacy in first two enrolled patients. The two patients achieved a CR and VGPR with Grade 1 cytokine release syndrome only 1 month after one dose of CAR-T cell infusion, and the responses lasted more than 12-month. Taken together, BCMA-7 × 19 CAR-T cells were safe and effective against refractory/relapsed multiple myeloma and thus warranted further clinical study., Competing Interests: AZ and JG were employed by Zhejiang Qixin Biotech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Duan, Wang, Wei, Feng, Liu, He, Xu, Wang, Zhao, Lv, Long, Lin, Zhao, Fang, Jiang, Tang and Gao.)
- Published
- 2021
- Full Text
- View/download PDF
28. Antibody treatment in multiple myeloma.
- Author
-
Maples KT, Johnson C, and Lonial S
- Subjects
- ADP-ribosyl Cyclase 1 antagonists & inhibitors, ADP-ribosyl Cyclase 1 immunology, Animals, Antibodies, Bispecific adverse effects, Antibodies, Bispecific immunology, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological immunology, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Humans, Immunoconjugates adverse effects, Immunoconjugates immunology, Multiple Myeloma immunology, Signaling Lymphocytic Activation Molecule Family antagonists & inhibitors, Signaling Lymphocytic Activation Molecule Family immunology, Antibodies, Bispecific therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Immunoconjugates therapeutic use, Multiple Myeloma drug therapy
- Abstract
Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and anti-SLAMF7 monoclonal antibodies were the first to enter the MM portfolio as treatment options for relapsed/ refractory MM. More recently, daratumumab has become important in the treatment of newly diagnosed MM, and a subcutaneous formulation has been approved. BCMA-targeted antibody-drug conjugates and bispecific antibodies, which are the newest antibody therapies to be investigated, provide additional therapeutic options for patients with heavily pretreated MM. This article reviews how antibody therapy has influenced the treatment of MM, describes the unique adverse event profiles of each relevant drug class, and explains how to incorporate antibody therapy into practice.
- Published
- 2021
29. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
- Author
-
Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, and Zhou J
- Subjects
- Adult, Aged, B-Cell Maturation Antigen immunology, Female, Humans, Leukemia, Plasma Cell immunology, Male, Middle Aged, Multiple Myeloma immunology, Remission Induction, Treatment Outcome, B-Cell Maturation Antigen antagonists & inhibitors, Immunotherapy, Adoptive methods, Leukemia, Plasma Cell drug therapy, Multiple Myeloma drug therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Background: Relapsed/refractory (R/R) multiple myeloma (MM) patients and primary plasma cell leukemia (PCL) have an unfavorable prognosis and no effective treatment. This study was designed to assess the safety and preliminary efficacy of a novel anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell in R/R MM and PCL., Methods: Between February 22, 2017, and June 25, 2018, 28 R/R and two R/R primary PCL patients received a median dose of 11.2 × 10
6 CAR+ cells/kg. The subjects were refractory to a proteasome inhibitor and/or an immunomodulatory agent. Fludarabine and cyclophosphamide were given as lymphodepletion chemotherapy., Results: Results for these 30 consecutive patients who received an anti-BCMA CAR T cell infusion are reported. The patients had received a median of four prior lines of therapy. A total of 44 different types of adverse events were recorded, and hematologic toxic effects were the most common events of any grade during treatment. Hematologic toxic effects were also the most common events of grade 3 or higher. A total of 29 patients (96.7%) had cytokine release syndrome, which was of grade 1 or 2 in 24 patients (80%) and grade 3 in five patients (16.7%). Neurologic toxic effects only occurred in one patient (3.3%) and were of grade 1. The objective response rate was 90%, and the complete response rate was 43.3%. With a median follow-up of 12.6 months, the median progression-free survival (PFS) and overall survival were 5.2 months and 14.0 months. One of the two primary PCL achieved a complete response with a PFS of 307 days. The other patients achieved a very good partial response with a PFS of 117 days., Conclusions: Anti-BCMA CAR T cell treatment is safe and highly active in R/R multiple myeloma., (© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)- Published
- 2021
- Full Text
- View/download PDF
30. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
- Author
-
Zhang Y, Zhang C, Zhou J, Zhang J, Chen X, Chen J, Wang P, Sun X, Lou X, Qi W, Kang L, Yu L, Wu D, and Li C
- Subjects
- B-Cell Maturation Antigen immunology, Biomarkers, Central Nervous System Neoplasms diagnosis, Glucocorticoids therapeutic use, Humans, Immunotherapy, Adoptive methods, Male, Middle Aged, Multiple Myeloma immunology, Multiple Myeloma therapy, Neurotoxicity Syndromes diagnosis, Receptors, Chimeric Antigen immunology, Symptom Assessment, T-Lymphocytes immunology, T-Lymphocytes metabolism, Treatment Outcome, Central Nervous System Neoplasms secondary, Immunotherapy, Adoptive adverse effects, Multiple Myeloma complications, Multiple Myeloma pathology, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes therapy
- Abstract
Isolated central nervous system involvement in multiple myeloma (CNS-MM) is rare and carries extremely poor prognosis. Chimeric antigen receptor T cell therapy (CART) targeting B-cell maturation antigen (BCMA) is demonstrated as a promising strategy in MM treatment, but the clinical safety and efficacy of BCMA-CART against isolated CNS-MM remain elusive. Here we report on a 56-year-old male with refractory isolated CNS-MM who received autologous BCMA-CART therapy and developed grade 4 neurological complications. Cerebrospinal fluid (CSF) analyses showed significant expansion of CART cells and a substantially elevated interleukin-6 (IL-6) level. Intravenous methylprednisolone was administered and the symptoms resolved gradually. Unexpectedly, the level of IL-6 in the CSF was maintained for another 3 days even after the relief of the neurological symptoms. A partial response was achieved and sustained for 5.5 months. This is the first report describing a patient with isolated CNS-MM treated using BCMA-CART therapy. The results demonstrated that BCMA-CART cells administered intravenously trafficked into the CSF, eradicated tumor cells, and induced severe but reversible neurological adverse events. This single-patient report suggests that BCMA-CART therapy can be considered as an alternative option for isolated CNS-MM., Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03196414., Competing Interests: CZ is an employee of Livzon Mabpharm, Inc and UniCar Therapy Ltd. XL and XS are employees of UniCar Therapy Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Zhang, Zhang, Zhou, Zhang, Chen, Chen, Wang, Sun, Lou, Qi, Kang, Yu, Wu and Li.)
- Published
- 2021
- Full Text
- View/download PDF
31. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
- Author
-
Jasiński M, Basak GW, and Jedrzejczak WW
- Subjects
- B-Cell Maturation Antigen immunology, Combined Modality Therapy, Humans, Multiple Myeloma immunology, Receptors, Antigen, T-Cell immunology, T-Lymphocytes transplantation, Immunotherapy, Adoptive, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
During recent years considerable progress has been made in the treatment of multiple myeloma. However, despite the current improvements in the prognosis of this malignancy, it always ends with relapse, and therefore new therapy approaches for destroying resistant cancer cells are needed. Presently, there is great hope being placed in the use of immunotherapy against refractory/relapsed multiple myeloma which is unresponsive to any other currently known drugs. The most promising one is CAR-T cell therapy which has already shown tremendous success in treating other malignancies such as acute lymphoblastic leukaemia (ALL) and could potentially be administered to multiple myeloma patients. CAR-T cells equipped with receptors against BCMA (B-cell maturation antigen), which is a surface antigen that is highly expressed on malignant cells, are now of great interest in this field with significant results in clinical trials. Furthermore, CAR-T cells with other receptors and combinations of different strategies are being intensively studied. However, even with CAR-T cell therapy, the majority of patients eventually relapse, which is the greatest limitation of this therapy. Serious adverse events such as cytokine release syndrome or neurotoxicity should also be considered as possible side effects of CAR-T cell therapy. Here, we discuss the results of CAR-T cell therapy in the treatment of multiple myeloma, where we describe its main advantages and disadvantages. Additionally, we also describe the current results that have been obtained on using combinations of CAR-T cell therapies with other drugs for the treatment of multiple myeloma., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Jasiński, Basak and Jedrzejczak.)
- Published
- 2021
- Full Text
- View/download PDF
32. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
- Author
-
Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, and Jagannath S
- Subjects
- Antibodies, Viral immunology, COVID-19 complications, COVID-19 diagnosis, COVID-19 immunology, COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Cough, Cyclophosphamide therapeutic use, Disease Progression, Fever, Hospitalization, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Multiple Myeloma complications, SARS-CoV-2, Vidarabine analogs & derivatives, Vidarabine therapeutic use, B-Cell Maturation Antigen immunology, COVID-19 physiopathology, Immunotherapy, Adoptive methods, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology
- Abstract
Background: Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. As a precautionary measure, many clinical studies halted enrollment during the initial surge of the global Novel Coronavirus Disease (COVID-19) pandemic. In this case report, we detail the successful treatment of a relapsed and refractory multiple myeloma (MM) patient treated with an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy immediately following clinical recovery from COVID-19., Case Presentation: The 57 year old Caucasian male patient had a 4-year history of MM and was considered penta-refractory upon presentation for CAR T cell therapy. He had a history of immunosuppression and received one dose of lymphodepleting chemotherapy (LDC) the day prior to COVID-19 diagnosis; this patient was able to mount a substantial immune response against the SARS-CoV-2 virus, and antiviral antibodies remain detectable 2 months after receiving anti-BCMA CAR T cell therapy. The recent SARS-CoV-2 infection in this patient did not exacerbate CAR T-associated cytokine release syndrome (CRS) and conversely the CAR T cell therapy did not result in COVID-19-related complications. One month after CAR T cell infusion, the patient was assessed to have an unconfirmed partial response per International Myeloma Working Group (IMWG) criteria., Conclusion: Our case adds important context around treatment choice for MM patients in the era of COVID-19 and whether CAR T therapy can be administered to patients who have recovered from COVID-19. As the COVID-19 global pandemic continues, the decision of whether to proceed with CAR T cell therapy will require extensive discussion weighing the potential risks and benefits of therapy. This case suggests that it is possible to successfully complete anti-BCMA CAR T cell therapy after recovery from COVID-19. CRB-402 study registered 6 September 2017 at clinicaltrials.gov (NCT03274219).
- Published
- 2021
- Full Text
- View/download PDF
33. Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.
- Author
-
Li X, Guo X, Zhu Y, Wei G, Zhang Y, Li X, Xu H, Cui J, Wu W, He J, Ritchie ME, Weiskittel TM, Li H, Yu H, Ding L, Shao M, Luo Q, Xu X, Teng X, Chang AH, Zhang J, Huang H, and Hu Y
- Subjects
- Antigens, CD19 immunology, Drug Resistance, Neoplasm, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Plasma Cell diagnosis, Leukemia, Plasma Cell immunology, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell metabolism, Recurrence, Single-Cell Analysis methods, T-Lymphocytes immunology, T-Lymphocytes metabolism, Treatment Outcome, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Leukemia, Plasma Cell genetics, Leukemia, Plasma Cell therapy, Transcriptome
- Abstract
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of hematological malignancies due to the prominent anti-tumor effects. B cell maturation antigen (BCMA) CAR-T cells have demonstrated promising effects in patients with relapsed/refractory multiple myeloma. However, the dynamics of CAR-T cell proliferation and cytotoxicity in clinical patients remains unexplored. Here, we longitudinally profiled the transcriptomes of 55,488 T cells including CAR-T products, CAR-T cells, and endogenous T cells at the peak and remission phases in a plasma cell leukemia (PCL) patient treated with BCMA CAR-T cells by single-cell transcriptomic analysis. Our results showed distinct CAR-T and endogenous T cell subsets indicating stage-specific expression in proliferation, cytotoxicity, and intercellular signaling pathways. Furthermore, we found that CAR-T cells at peak phase gradually convert to a highly cytotoxic state from a highly proliferative state along a development trajectory. Moreover, re-analysis of a single cell study from CD8
+ CD19 CAR-T confirmed our findings. These commonalities suggest conserved mechanisms for CAR-T treatment across hematological malignancies. Taken together, our current study provides insight into CAR-T cell dynamics during CAR-T therapy and proves that both BCMA CAR-T and CD19 CAR-T have similar transcriptional characteristics, especially at the CAR-T peak phase., (Copyright © 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
34. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
- Author
-
Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, and Fu C
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Immunotherapy, Adoptive methods, Male, Middle Aged, Multiple Myeloma immunology, Multiple Myeloma pathology, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local pathology, Prognosis, Salvage Therapy, Survival Rate, Antigens, CD19 immunology, B-Cell Maturation Antigen immunology, Drug Resistance, Neoplasm, Immunotherapy, Adoptive mortality, Multiple Myeloma therapy, Neoplasm Recurrence, Local therapy, Receptors, Chimeric Antigen immunology
- Abstract
The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T-cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19-CART and B-cell maturation antigen (BCMA)-CARTs for RRMM with a similar 3 + 3 dose escalation combined with a toxicity sentinel design. We enrolled 10 patients, among whom 7 received autologous infusion and 3 received allogeneic infusion. The median follow-up time was 20 months. The most common grade 3/4 treatment-emergent toxicities were hematological toxicities. Cytokine-release syndrome (CRS) adverse reactions were grade 1/2 in 9 out of 10 subjects. No dose-limited toxicity (DLT) was observed for BCMA-CAR-positive T cells ≤5 × 10
7 /kg), while two patients with dose-levels of 5-6.5 × 107 /kg experienced DLTs. The overall response rate was 90% (five partial responses and four stringent complete responses). Three out of four patients with stringent complete responses to autologous CART had progression-free survival for over 2 years. The three patients with allogeneic CART experienced disease progression within 2 months. These results evidence the sequential infusion's preliminarily tolerability and efficacy in RRMM, and present a simple and safe design applicable for the establishment of multiple CART therapy., (© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
35. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.
- Author
-
Chen W, Yang F, Wang C, Narula J, Pascua E, Ni I, Ding S, Deng X, Chu ML, Pham A, Jiang X, Lindquist KC, Doonan PJ, Van Blarcom T, Yeung YA, and Chaparro-Riggers J
- Subjects
- Animals, Antibodies, Bispecific genetics, Antibodies, Bispecific immunology, Antibodies, Bispecific metabolism, Antibody-Dependent Cell Cytotoxicity, Antigen-Antibody Reactions, B-Cell Maturation Antigen immunology, Binding Sites, Antibody, Biological Products immunology, Biological Products metabolism, CD3 Complex immunology, CD3 Complex metabolism, Cell Line, Tumor, Cytokines metabolism, Epitope Mapping, Humans, Immunoglobulin G genetics, Immunoglobulin G immunology, Immunoglobulin G metabolism, Immunological Synapses drug effects, Immunological Synapses immunology, Immunological Synapses metabolism, Kinetics, Receptors, Antigen, T-Cell immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism, fms-Like Tyrosine Kinase 3 immunology, fms-Like Tyrosine Kinase 3 metabolism, Antibodies, Bispecific pharmacology, B-Cell Maturation Antigen metabolism, Biological Products pharmacology, Epitopes, Immunoglobulin G pharmacology, Protein Engineering, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes drug effects
- Abstract
T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short antigen-binding arm distance, with our bispecific IgG platform. By generating diverse panels of antigen-expressing cells where B cell maturation antigen is either tethered to the cell membrane or located to the juxtamembrane region and masked by elongated structural spacer units, we presented a systematic approach to investigate the role of antigen epitope location and molecular formats in immunological synapse formation and cytotoxicity. We demonstrated that diabody-Fc is more potent for antigen epitopes located in the membrane distal region, while bispecific IgG is more efficient for membrane-proximal epitopes. Additionally, we explored other parameters, including receptor density, antigen-binding affinity, and kinetics. Our results show that molecular format and antigen epitope location, which jointly determine the intermembrane distance between target cells and T cells, allow decoupling of cytotoxicity and cytokine release, while antigen-binding affinities appear to be positively correlated with both readouts. Our work offers new insight that could potentially lead to a wider therapeutic window for T-cell engaging biologics in general.
- Published
- 2021
- Full Text
- View/download PDF
36. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
- Author
-
Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, and Anguille S
- Subjects
- Cytokine Release Syndrome etiology, Cytokine Release Syndrome immunology, Humans, Immunotherapy, Adoptive methods, Multiple Myeloma immunology, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes immunology, Progression-Free Survival, Receptors, Chimeric Antigen immunology, Treatment Outcome, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive adverse effects, Multiple Myeloma therapy, Receptors, Chimeric Antigen therapeutic use
- Abstract
Background: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing these outcomes., Methods: We performed a database search using the terms "BCMA," "CAR," and "multiple myeloma" for clinical studies published between 01/01/2015 and 01/01/2020. The methodology is further detailed in PROSPERO (CRD42020125332)., Results: Twenty-three different CAR-T-cell products have been used so far in 640 patients. Cytokine release syndrome was observed in 80.3% (69.0-88.2); 10.5% (6.8-16.0) had neurotoxicity. A higher neurotoxicity rate was reported in studies that included more heavily pretreated patients: 19.1% (13.3-26.7; I
2 = 45%) versus 2.8% (1.3-6.1; I2 = 0%) (p < 0.0001). The pooled overall response rate was 80.5% (73.5-85.9); complete responses (CR) were observed in 44.8% (35.3-54.6). A pooled CR rate of 71.9% (62.8-79.6; I2 = 0%) was noted in studies using alpaca/llama-based constructs, whereas it was only 18.0% (6.5-41.1; I2 = 67%) in studies that used retroviral vectors for CAR transduction. Median progression-free survival (PFS) was 12.2 (11.4-17.4) months, which compared favorably to the expected PFS of 1.9 (1.5-3.7) months (HR 0.14; p < 0.0001)., Conclusions: Although considerable toxicity was observed, BCMA-targeted CAR-T-cell therapy is highly efficacious even in advanced multiple myeloma. Subgroup analysis confirmed the anticipated inter-study heterogeneity and identified potential factors contributing to safety and efficacy. The results of this meta-analysis may assist the future design of CAR-T-cell studies and lead to optimized BCMA CAR-T-cell products.- Published
- 2020
- Full Text
- View/download PDF
37. Current antibody-based therapies for the treatment of multiple myeloma.
- Author
-
Varga C, Waldschmidt JM, Gandolfi S, and Richardson PG
- Subjects
- ADP-ribosyl Cyclase 1 antagonists & inhibitors, ADP-ribosyl Cyclase 1 immunology, Antineoplastic Agents, Immunological immunology, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Humans, Membrane Glycoproteins antagonists & inhibitors, Membrane Glycoproteins immunology, Multiple Myeloma immunology, Multiple Myeloma pathology, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins immunology, Signaling Lymphocytic Activation Molecule Family antagonists & inhibitors, Signaling Lymphocytic Activation Molecule Family immunology, Antineoplastic Agents, Immunological therapeutic use, Multiple Myeloma drug therapy
- Abstract
Despite continued and considerable progress following the introduction of proteasome inhibitors and immunomodulatory agents, multiple myeloma (MM) remains an incurable disease, and new therapeutic strategies are urgently needed. Monoclonal antibodies represent a well-established targeted approach to the treatment of MM, with selective killing properties and limited off-target toxicity. Since their approval, the anti-CD38 agent daratumumab, the anti-SLAMF7 agent elotuzumab, and most recently the anti-CD38 agent isatuximab have led to pivotal improvements in the treatment of double-refractory MM; currently, they are on their way to becoming integral parts in the up-front care of patients who have newly diagnosed MM, with daratumumab already approved in this setting. Several other antibody-based strategies are undergoing clinical assessment in MM. Although the investigation of checkpoint inhibitors in MM has been halted, bispecific T-cell engagers and especially antibody-drug conjugates demonstrate encouraging efficacy and manageable toxicity in triple class-refractory MM. The accelerated approval of belantamab mafodotin represents an important milestone in antibody development; its ability to target B-cell maturation antigen (BCMA) in advanced disease is now established. Here, we present an overview of the currently available monoclonal antibody treatments in MM and discuss the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.
- Published
- 2020
38. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
- Author
-
Bera TK
- Subjects
- Animals, B-Cell Maturation Antigen immunology, Gene Expression Regulation, Neoplastic drug effects, Humans, Immunoglobulin Variable Region immunology, Immunoglobulin Variable Region therapeutic use, Immunotoxins immunology, Mice, Multiple Myeloma genetics, Multiple Myeloma immunology, Multiple Myeloma pathology, Recombinant Proteins immunology, Recombinant Proteins therapeutic use, Xenograft Model Antitumor Assays, B-Cell Maturation Antigen therapeutic use, Cell Proliferation drug effects, Immunotoxins therapeutic use, Multiple Myeloma drug therapy
- Abstract
Multiple myeloma (MM) is a B-cell malignancy that is incurable for a majority of patients. B-cell maturation antigen (BCMA) is a lineage-restricted differentiation protein highly expressed in multiple myeloma cells but not in other normal tissues except normal plasma B cells. Due to the restricted expression and being a cell surface membrane protein, BCMA is an ideal target for immunotherapy approaches in MM. Recombinant immunotoxins (RITs) are a novel class of protein therapeutics that are composed of the Fv or Fab portion of an antibody fused to a cytotoxic agent. RITs were produced by expressing plasmids encoding the components of the anti-BCMA RITs in E. coli followed by inclusion body preparation, solubilization, renaturation, and purification by column chromatography. The cytotoxic activity of RITs was tested in vitro by WST-8 assays using BCMA expressing cell lines and on cells isolated from MM patients. The in vivo efficacy of RITs was tested in a xenograft mouse model using BCMA expressing multiple myeloma cell lines. Anti-BCMA recombinant immunotoxins are very effective in killing myeloma cell lines and cells isolated from myeloma patients expressing BCMA. Two mouse models of myeloma showed that the anti-BCMA immunotoxins can produce a long-term complete response and warrant further preclinical development.
- Published
- 2020
- Full Text
- View/download PDF
39. BCMA-targeted immunotherapy for multiple myeloma.
- Author
-
Yu B, Jiang T, and Liu D
- Subjects
- Antibodies, Bispecific therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, B-Cell Maturation Antigen genetics, B-Cell Maturation Antigen immunology, B-Cell Maturation Antigen physiology, B-Lymphocytes immunology, B-Lymphocytes metabolism, B-Lymphocytes pathology, Clinical Trials as Topic, Humans, Immunoconjugates therapeutic use, Immunotherapy, Adoptive, Multicenter Studies as Topic, Multiple Myeloma immunology, Neoplasm Proteins genetics, Neoplasm Proteins immunology, Neoplasm Proteins physiology, Plasma Cells drug effects, Plasma Cells metabolism, Protein Isoforms antagonists & inhibitors, Protein Isoforms immunology, Randomized Controlled Trials as Topic, B-Cell Maturation Antigen antagonists & inhibitors, Immunotherapy, Molecular Targeted Therapy, Multiple Myeloma therapy, Neoplasm Proteins antagonists & inhibitors
- Abstract
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
- Published
- 2020
- Full Text
- View/download PDF
40. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
- Author
-
Abramson HN
- Subjects
- Antibodies, Monoclonal, Humanized immunology, Antibodies, Monoclonal, Humanized therapeutic use, B-Cell Maturation Antigen metabolism, B-Lymphocytes immunology, Hematopoietic Stem Cell Transplantation, Humans, Multiple Myeloma pathology, Neoplasm Recurrence, Local, Antibodies, Monoclonal, Humanized pharmacology, B-Cell Maturation Antigen immunology, Drug Development methods, Immunotherapy, Adoptive methods, Multiple Myeloma immunology, Receptors, Chimeric Antigen immunology, Tumor Necrosis Factor Ligand Superfamily Member 13 immunology
- Abstract
During the past two decades there has been a major shift in the choice of agents to treat multiple myeloma, whether newly diagnosed or in the relapsed/refractory stage. The introduction of new drug classes, such as proteasome inhibitors, immunomodulators, and anti-CD38 and anti-SLAMF7 monoclonal antibodies, coupled with autologous stem cell transplantation, has approximately doubled the disease's five-year survival rate. However, this positive news is tempered by the realization that these measures are not curative and patients eventually relapse and/or become resistant to the drug's effects. Thus, there is a need to discover newer myeloma-driving molecular markers and develop innovative drugs designed to precisely regulate the actions of such putative targets. B cell maturation antigen (BCMA), which is found almost exclusively on the surfaces of malignant plasma cells to the exclusion of other cell types, including their normal counterparts, has emerged as a specific target of interest in this regard. Immunotherapeutic agents have been at the forefront of research designed to block BCMA activity. These agents encompass monoclonal antibodies, such as the drug conjugate belantamab mafodotin; bispecific T-cell engager strategies exemplified by AMG 420; and chimeric antigen receptor (CAR) T-cell therapeutics that include idecabtagene vicleucel (bb2121) and JNJ-68284528.
- Published
- 2020
- Full Text
- View/download PDF
41. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
- Author
-
Nair-Gupta P, Rudnick SI, Luistro L, Smith M, McDaid R, Li Y, Pillarisetti K, Joseph J, Heidrich B, Packman K, Attar R, and Gaudet F
- Subjects
- Animals, Antibodies, Bispecific pharmacology, Antibodies, Bispecific therapeutic use, Antineoplastic Agents, Immunological therapeutic use, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Bone Marrow immunology, Bone Marrow pathology, CD3 Complex antagonists & inhibitors, Cell Line, Tumor, Female, Humans, Integrin alpha4beta1 immunology, Interleukin-3 Receptor alpha Subunit antagonists & inhibitors, Interleukin-3 Receptor alpha Subunit immunology, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute pathology, Mice, Multiple Myeloma immunology, Multiple Myeloma pathology, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes pathology, Tumor Microenvironment drug effects, Antineoplastic Agents, Immunological pharmacology, Bone Marrow drug effects, CD3 Complex immunology, Integrin alpha4beta1 antagonists & inhibitors, Leukemia, Myeloid, Acute drug therapy, Multiple Myeloma drug therapy
- Abstract
Redirecting T cells to specifically kill malignant cells has been validated as an effective anti-cancer strategy in the clinic with the approval of blinatumomab for acute lymphoblastic leukemia. However, the immunosuppressive nature of the tumor microenvironment potentially poses a significant hurdle to T cell therapies. In hematological malignancies, the bone marrow (BM) niche is protective to leukemic stem cells and has minimized the efficacy of several anti-cancer drugs. In this study, we investigated the impact of the BM microenvironment on T cell redirection. Using bispecific antibodies targeting specific tumor antigens (CD123 and BCMA) and CD3, we observed that co-culture of acute myeloid leukemia or multiple myeloma cells with BM stromal cells protected tumor cells from bispecific antibody-T cell-mediated lysis in vitro and in vivo. Impaired CD3 redirection cytotoxicity was correlated with reduced T cell effector responses and cell-cell contact with stromal cells was implicated in reducing T cell activation and conferring protection of cancer cells. Finally, blocking the VLA4 adhesion pathway in combination with CD3 redirection reduced the stromal-mediated inhibition of cytotoxicity and T cell activation. Our results lend support to inhibiting VLA4 interactions along with administering CD3 redirection therapeutics as a novel combinatorial regimen for robust anti-cancer responses.
- Published
- 2020
- Full Text
- View/download PDF
42. Advances in CAR T-cell therapy for the treatment of multiple myeloma.
- Author
-
Shah N
- Subjects
- Humans, Adoptive Transfer, Antigens, Neoplasm immunology, B-Cell Maturation Antigen immunology, Multiple Myeloma immunology, Multiple Myeloma pathology, Multiple Myeloma therapy
- Published
- 2020
43. Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
- Author
-
Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, Verkleij CPM, Boominathan R, Vaidya B, Sendecki J, Axel A, Gaudet F, Pillarisetti K, Zweegman S, Adams HC 3rd, Mutis T, and van de Donk NWCJ
- Subjects
- Antibodies, Bispecific immunology, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents pharmacology, Bone Marrow pathology, Drug Evaluation, Preclinical, Drug Synergism, Drug Therapy, Combination, Humans, Immunotherapy methods, Multiple Myeloma immunology, Multiple Myeloma metabolism, Multiple Myeloma pathology, Tumor Cells, Cultured, Antibodies, Bispecific pharmacology, Antibodies, Monoclonal pharmacology, B-Cell Maturation Antigen immunology, CD3 Complex immunology, Multiple Myeloma drug therapy
- Abstract
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor outcome, indicating the need for new agents with novel mechanisms of action., Experimental Design: We evaluated the anti-MM activity of the fully human BCMA×CD3 bispecific antibody JNJ-7957 in cell lines and bone marrow (BM) samples. The impact of several tumor- and host-related factors on sensitivity to JNJ-7957 therapy was also evaluated., Results: We show that JNJ-7957 has potent activity against 4 MM cell lines, against tumor cells in 48 of 49 BM samples obtained from MM patients, and in 5 of 6 BM samples obtained from primary plasma cell leukemia patients. JNJ-7957 activity was significantly enhanced in patients with prior daratumumab treatment, which was partially due to enhanced killing capacity of daratumumab-exposed effector cells. BCMA expression did not affect activity of JNJ-7957. High T-cell frequencies and high effector:target ratios were associated with improved JNJ-7957-mediated lysis of MM cells. The PD-1/PD-L1 axis had a modest negative impact on JNJ-7957 activity against tumor cells from daratumumab-naïve MM patients. Soluble BCMA impaired the ability of JNJ-7957 to kill MM cells, although higher concentrations were able to overcome this negative effect., Conclusions: JNJ-7957 effectively kills MM cells ex vivo , including those from heavily pretreated MM patients, whereby several components of the immunosuppressive BM microenvironment had only modest effects on its killing capacity. Our findings support the ongoing trial with JNJ-7957 as single agent and provide the preclinical rationale for evaluating JNJ-7957 in combination with daratumumab in MM., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
44. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
- Author
-
Caraccio C, Krishna S, Phillips DJ, and Schürch CM
- Subjects
- ADP-ribosyl Cyclase 1 immunology, Animals, B-Cell Maturation Antigen immunology, Cell Differentiation, Clinical Trials as Topic, Epitopes, Humans, Leukemia, Plasma Cell immunology, Multiple Myeloma immunology, Risk, Antibodies, Bispecific therapeutic use, B-Lymphocytes physiology, Leukemia, Plasma Cell therapy, Multiple Myeloma therapy
- Abstract
Multiple myeloma (MM) is a plasma cell malignancy and the second most common hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence of ~30,770 cases in the United States, MM has a high mortality rate, leading to 12,770 deaths per year. MM is a genetically complex, highly heterogeneous malignancy, with significant inter- and intra-patient clonal variability. Recent years have witnessed dramatic improvements in the diagnostics, classification, and treatment of MM. However, patients with high-risk disease have not yet benefited from therapeutic advances. High-risk patients are often primary refractory to treatment or relapse early, ultimately resulting in progression toward aggressive end-stage MM, with associated extramedullary disease or plasma cell leukemia. Therefore, novel treatment modalities are needed to improve the outcomes of these patients. Bispecific antibodies (BsAbs) are immunotherapeutics that simultaneously target and thereby redirect effector immune cells to tumor cells. BsAbs have shown high efficacy in B cell malignancies, including refractory/relapsed acute lymphoblastic leukemia. Various BsAbs targeting MM-specific antigens such as B cell maturation antigen (BCMA), CD38, and CD138 are currently in pre-clinical and clinical development, with promising results. In this review, we outline these advances, focusing on BsAb drugs, their targets, and their potential to improve survival, especially for high-risk MM patients. In combination with current treatment strategies, BsAbs may pave the way toward a cure for MM., (Copyright © 2020 Caraccio, Krishna, Phillips and Schürch.)
- Published
- 2020
- Full Text
- View/download PDF
45. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
- Author
-
Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, and Roliński J
- Subjects
- Antigens, CD1d immunology, B-Cell Maturation Antigen metabolism, Humans, Integrin beta Chains metabolism, Receptors, Chimeric Antigen metabolism, Risk Assessment, Syndecan-1 immunology, Syndecan-1 metabolism, B-Cell Maturation Antigen immunology, Cell- and Tissue-Based Therapy methods, Immunotherapy, Adoptive methods, Multiple Myeloma immunology, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Despite the significant progress of modern anticancer therapies, multiple myeloma (MM) is still incurable for the majority of patients. Following almost three decades of development, chimeric antigen receptor (CAR) T-cell therapy now has the opportunity to revolutionize the treatment landscape and meet the unmet clinical need. However, there are still several major hurdles to overcome. Here we discuss the recent advances of CAR T-cell therapy for MM with an emphasis on future directions and possible risks. Currently, CAR T-cell therapy for MM is at the first stage of clinical studies, and most studies have focused on CAR T cells targeting B cell maturation antigen (BCMA), but other antigens such as cluster of differentiation 138 (CD138, syndecan-1) are also being evaluated. Although this therapy is associated with side effects, such as cytokine release syndrome and neurotoxicity, and relapses have been observed, the benefit-risk balance and huge potential drive the ongoing clinical progress. To fulfill the promise of recent clinical trial success and maximize the potential of CAR T, future efforts should focus on the reduction of side effects, novel targeted antigens, combinatorial uses of different types of CAR T, and development of CAR T cells targeting more than one antigen.
- Published
- 2020
- Full Text
- View/download PDF
46. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
- Author
-
Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee HG, Stevanović S, and Walz JS
- Subjects
- Antibodies, Monoclonal immunology, Case-Control Studies, Feasibility Studies, Healthy Volunteers, Humans, Immunotherapy methods, Multiple Myeloma metabolism, Multiple Myeloma therapy, Neoplasm Proteins immunology, B-Cell Maturation Antigen immunology, CD8-Positive T-Lymphocytes immunology, Epitopes, T-Lymphocyte immunology, Mass Spectrometry methods, Multiple Myeloma immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
The B-cell maturation antigen (BCMA) is currently being evaluated as promising tumor-associated surface antigen for T-cell-based immunotherapy approaches, such as CAR T cells and bispecific antibodies, in multiple myeloma (MM). Cytotoxic T cells bearing BCMA-specific T-cell receptors might further allow targeting HLA-presented antigens derived from the intracellular domain of BCMA. By analyzing a mass spectrometry-acquired immunopeptidome dataset of primary MM samples and MM cell lines for BCMA-derived HLA ligands, we identified the naturally presented HLA-B*18-restricted ligand P(BCMA)
B*18 . Additionally, P(BCMA)B*18 was identified on primary CLL samples, thereby expanding the range for possible applications. P(BCMA)B*18 induced multifunctional BCMA-specific cells de novo from naïve CD8+ T cells of healthy volunteers. These T cells exhibited antigen-specific lysis of autologous peptide-loaded cells. Even in the immunosuppressive context of MM, we detected spontaneous memory T-cell responses against P(BCMA)B*18 in patients. By applying CTLA-4 and PD-1 inhibition in vitro we induced multifunctional P(BCMA)B*18 -specific CD8+ T cells in MM patients lacking preexisting BCMA-directed immune responses. Finally, we could show antigen-specific lysis of autologous peptide-loaded target cells and even MM.1S cells naturally presenting P(BCMA)B*18 using patient-derived P(BCMA)B*18 -specific T cells. Hence, this BCMA-derived T-cell epitope represents a promising target for T-cell-based immunotherapy and monitoring following immunotherapy in B-cell malignancy patients.- Published
- 2020
- Full Text
- View/download PDF
47. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
- Author
-
Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, and Kochenderfer JN
- Subjects
- Animals, B-Cell Maturation Antigen immunology, Cell Line, Tumor, Cell Survival, Cells, Cultured, Humans, Leukocytes, Mononuclear immunology, Mice, Nerve Tissue Proteins genetics, Nerve Tissue Proteins immunology, Protein Domains genetics, Protein Domains immunology, Protein Engineering, Receptors, Chimeric Antigen metabolism, Receptors, Nerve Growth Factor genetics, Receptors, Nerve Growth Factor immunology, Single-Chain Antibodies genetics, Single-Chain Antibodies immunology, Single-Chain Antibodies metabolism, Immunoglobulin Heavy Chains metabolism, Receptors, Chimeric Antigen genetics, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Chimeric antigen receptor (CAR)-expressing T cells targeting B-cell maturation antigen (BCMA) have activity against multiple myeloma, but improvements in anti-BCMA CARs are needed. We demonstrated recipient anti-CAR T-cell responses against a murine single-chain variable fragment (scFv) used clinically in anti-BCMA CARs. To bypass potential anti-CAR immunogenicity and to reduce CAR binding domain size, here we designed CARs with antigen-recognition domains consisting of only a fully human heavy-chain variable domain without a light-chain domain. A CAR designated FHVH33-CD8BBZ contains a fully human heavy-chain variable domain (FHVH) plus 4-1BB and CD3ζ domains. T cells expressing FHVH33-CD8BBZ exhibit similar cytokine release, degranulation, and mouse tumor eradication as a CAR that is identical except for substitution of a scFv for FHVH33. Inclusion of 4-1BB is critical for reducing activation-induced cell death and promoting survival of T cells expressing FHVH33-containing CARs. Our results indicate that heavy-chain-only anti-BCMA CARs are suitable for evaluation in a clinical trial.
- Published
- 2020
- Full Text
- View/download PDF
48. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
- Author
-
Nelke J, Medler J, Weisenberger D, Beilhack A, and Wajant H
- Subjects
- Antibodies, Monoclonal genetics, B-Cell Activating Factor genetics, B-Cell Activation Factor Receptor genetics, B-Cell Activation Factor Receptor immunology, B-Cell Maturation Antigen genetics, B-Cell Maturation Antigen immunology, HEK293 Cells, Humans, Immunoglobulin Fab Fragments genetics, Jurkat Cells, Recombinant Fusion Proteins genetics, Transmembrane Activator and CAML Interactor Protein genetics, Transmembrane Activator and CAML Interactor Protein immunology, Antibodies, Monoclonal immunology, B-Cell Activating Factor immunology, B-Cell Activation Factor Receptor agonists, B-Cell Maturation Antigen agonists, CD40 Antigens immunology, Immunoglobulin Fab Fragments immunology, Recombinant Fusion Proteins immunology, Transmembrane Activator and CAML Interactor Protein agonists, fas Receptor immunology
- Abstract
Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchoring through the antibody's Fc domain and does not involve the engagement of FcγR signaling. The aim of this study was to elicit agonistic activity from αCD40 and αCD95 antibodies in a myeloma cell anchoring-controlled FcγR-independent manner. For this purpose, various antibody variants (IgG1, IgG1
N297A , Fab2 ) against the TNFRSF members CD40 and CD95 were genetically fused to a single-chain-encoded B-cell activating factor (scBaff) trimer as a C-terminal myeloma-specific anchoring domain substituting for Fc domain-mediated FcγR binding. The antibody-scBaff fusion proteins were evaluated in binding studies and functional assays using tumor cell lines expressing one or more of the three receptors of Baff: BaffR, transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). Cellular binding studies showed that the binding properties of the different domains within the fusion proteins remained fully intact in the antibody-scBaff fusion proteins. In co-culture assays of CD40- and CD95-responsive cells with BaffR, BCMA or TACI expressing anchoring cells, the antibody fusion proteins displayed strong agonism while only minor receptor stimulation was observed in co-cultures with cells without expression of Baff-interacting receptors. Thus, our CD40 and CD95 antibody fusion proteins display myeloma cell-dependent activity and promise reduced systemic side effects compared to conventional CD40 and CD95 agonists.- Published
- 2020
- Full Text
- View/download PDF
49. Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma.
- Author
-
Tang F, Lu Y, Ge Y, Shang J, and Zhu X
- Subjects
- Aged, Antigens, CD19 immunology, B-Cell Maturation Antigen immunology, Cytokine Release Syndrome diagnosis, Cytokine Release Syndrome immunology, Drug Resistance, Neoplasm immunology, Female, Humans, Immunotherapy, Adoptive adverse effects, Incidence, Infusions, Intravenous, Male, Middle Aged, Multiple Myeloma immunology, Multiple Myeloma pathology, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism, Treatment Outcome, Cytokine Release Syndrome epidemiology, Immunotherapy, Adoptive methods, Multiple Myeloma therapy, T-Lymphocytes transplantation
- Published
- 2020
- Full Text
- View/download PDF
50. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
- Author
-
Huang H, Wu HW, and Hu YX
- Subjects
- ADP-ribosyl Cyclase 1 immunology, B-Cell Maturation Antigen immunology, Humans, Immunotherapy, Adoptive adverse effects, Multiple Myeloma immunology, Receptors, G-Protein-Coupled immunology, Signaling Lymphocytic Activation Molecule Family immunology, Syndecan-1 immunology, Immunotherapy, Adoptive methods, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Multiple myeloma (MM), considered an incurable hematological malignancy, is characterized by its clonal evolution of malignant plasma cells. Although the application of autologous stem cell transplantation (ASCT) and the introduction of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) have doubled the median overall survival to eight years, relapsed and refractory diseases are still frequent events in the course of MM. To achieve a durable and deep remission, immunotherapy modalities have been developed for relapsed/refractory multiple myeloma (RRMM). Among these approaches, chimeric antigen receptor (CAR) T-cell therapy is the most promising star, based on the results of previous success in B-cell neoplasms. In this immunotherapy, autologous T cells are engineered to express an artificial receptor which targets a tumor-associated antigen and initiates the T-cell killing procedure. Tisagenlecleucel and Axicabtagene, targeting the CD19 antigen, are the two pacesetters of CAR T-cell products. They were approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Their development enabled unparalleled efficacy in combating hematopoietic neoplasms. In this review article, we summarize six promising candidate antigens in MM that can be targeted by CARs and discuss some noteworthy studies of the safety profile of current CAR T-cell therapy.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.